Nasdaq Stockholm Welcomes Asarina Pharma to First North
Stockholm, September 24, 2018— Nasdaq (Nasdaq: NDAQ) today announced that trading in Asarina Pharma AB’s shares (short name: ASAP) commences today on Nasdaq First North in Stockholm. Read Nasdaq First North's Press Release below, or HERE.
Stockholm, September 24, 2018— Nasdaq (Nasdaq: NDAQ) announces that the trading in Asarina Pharma AB’s shares (short name: ASAP) will commence today on Nasdaq First North in Stockholm. Asarina Pharma belongs to the health care sector and is the 57th company to be admitted to trading on Nasdaq’s Nordic markets* in 2018.
Asarina Pharma is a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Its product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With its new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), the company aims to deliver a new generation of safe, targeted treatments for still widely untreated conditions, and to become a leading specialty pharma company in Women’s Health. Asarina Pharma is headquartered in Solna, Sweden. For more information, please visit www.asarinapharma.com.
“We’re confident that the integrity and dynamism of Nasdaq First North will play an important part in helping us reach our business and medical goals,” said Peter Nordkild, CEO of Asarina Pharma. “We’re delighted to be part of such a vibrant, informed market. The capital and commitment our new shareholders have already invested in us is highly valued, and we look forward to welcoming even more as we move forward.”
”We welcome Asarina Pharma to our European growth market, Nasdaq First North,” said Adam Kostyál, SVP and Head of European Listings, Nasdaq. “Asarina Pharma joins our strong health care sector, and we look forward to supporting the company with the visibility and investor exposure that comes with a Nasdaq First North listing.”
Asarina Pharma AB has appointed Erik Penser Bank AB as the Certified Adviser.
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
About Nasdaq First North
Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 100 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 4,000 total listings with a market value of $14 trillion. To learn more, visit: http://business.nasdaq.com
For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46, e-mail: peter.nordkild@asarinapharma.com
TO THE EDITORS
About Asarina Pharma AB
We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of safe, targeted treatments for still widely untreated conditions, and to become a leading specialty pharma company in Women’s Health.
For more information, please visit: www.asarinapharma.com
Tags: